DiaMedica Therapeutics (NASDAQ:DMAC) Trading Down 3.6%

DiaMedica Therapeutics Inc. (NASDAQ:DMAC)’s share price was down 3.6% on Tuesday . The company traded as low as $2.41 and last traded at $2.42. Approximately 5,238 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 41,772 shares. The stock had previously closed at $2.51.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on DMAC. Oppenheimer reissued an “outperform” rating and issued a $6.00 price target (down from $7.00) on shares of DiaMedica Therapeutics in a report on Thursday, March 21st. Craig Hallum began coverage on shares of DiaMedica Therapeutics in a report on Wednesday. They issued a “buy” rating and a $8.00 price target for the company.

DiaMedica Therapeutics Trading Up 3.3 %

The company’s fifty day simple moving average is $2.80 and its 200 day simple moving average is $2.69. The stock has a market capitalization of $96.03 million, a P/E ratio of -4.08 and a beta of 1.69.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its quarterly earnings results on Wednesday, March 20th. The company reported ($0.14) EPS for the quarter, meeting the consensus estimate of ($0.14). Equities research analysts predict that DiaMedica Therapeutics Inc. will post -0.69 earnings per share for the current year.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds have recently made changes to their positions in DMAC. Stonebridge Capital Advisors LLC bought a new stake in shares of DiaMedica Therapeutics during the 3rd quarter worth $52,000. Avantax Advisory Services Inc. bought a new stake in shares of DiaMedica Therapeutics during the 4th quarter worth $36,000. Finally, Paragon Associates & Paragon Associates II Joint Venture lifted its holdings in shares of DiaMedica Therapeutics by 6.4% during the 4th quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 500,000 shares of the company’s stock worth $1,420,000 after acquiring an additional 30,000 shares during the last quarter. 10.12% of the stock is owned by institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.